Donald Trump launches made in America smartphone, Trump T1 Mobile: Here's its price and specifications
US President
Donald Trump
's business empire expanded into telecommunications Monday with the launch of
Trump Mobile
's T1 smartphone, featuring "made in America" manufacturing and domestic customer support centers, according to Reuters. "We've partnered with some of the greatest people in the industry to make sure that real Americans get true value from their mobile carriers,"
Trump
Jr. said.
The announcement came on the 10-year anniversary of Trump's 2016 presidential campaign launch. The venture, unveiled by Donald Trump Jr. and
Eric Trump
at Trump Tower in New York, positions itself as an alternative to major carriers while capitalizing on the Trump brand's appeal to conservative consumers. The service will operate as a Mobile Virtual Network Operator, purchasing network capacity from the three major U.S. wireless providers.
Trump's T1 Mobile is a gold-colored Android smartphone priced at $499: Here's the rest of specifications
Trump Mobile will release the T1 Phone in August, priced at $499 (around Rs 42,893) with a $100 down payment. The gold-colored smartphone boasts a 6.8-inch AMOLED display with 120Hz refresh rate, 50MP main camera, 5000mAh battery, and runs Android 15. The device features 12GB RAM, 256GB expandable storage, and includes both fingerprint and AI face unlock security.
Marketed as "designed and built in the United States," the T1 Phone targets customers seeking American-made alternatives in a market dominated by foreign manufacturers. The smartphone industry sees over 60 million annual purchases in the U.S., with nearly all devices manufactured overseas.
Donald Trump's 'The 47 Plan' offers unlimited calling, text, data and free international calling
The service plan, which the Trump Mobile says it's top tier offering, costs $47.45 (around Rs 4,0787) monthly, referencing Trump as the 47th president. The benefit includes unlimited talk, text and data without contracts or credit checks. Additional benefits encompass 24/7 roadside assistance, telehealth services, device protection, and free international calling to over 100 countries.
The service emphasizes support for military families with free long-distance calling to overseas bases. A 250-seat customer service center staffed by real people, not automated systems, will operate 24/7 from the United States.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
41 minutes ago
- Time of India
Meta's $14.8 billion scale AI deal latest test of AI partnerships
By Jody Godoy Facebook owner Meta 's $14.8 billion investment in Scale AI and hiring of the data-labeling startup's CEO will test how the Trump administration views so-called acquihire deals , which some have criticized as an attempt to evade regulatory scrutiny. The deal, announced on Thursday, was Meta's second-largest investment to date. It gives the owner of Facebook a 49% nonvoting stake in Scale AI, which uses gig workers to manually label data and includes among its customers Meta competitors Microsoft and ChatGPT creator OpenAI. Unlike an acquisition or a transaction that would give Meta a controlling stake, the deal does not require a review by U.S. antitrust regulators. However, they could probe the deal if they believe it was structured to avoid those requirements or harm competition. The deal appeared to be structured to avoid potential pitfalls, such as cutting off competitors' access to Scale's services or giving Meta an inside view into rivals' operations - though Reuters exclusively reported on Friday that Alphabet's Google has decided to sever ties with Scale in light of Meta's stake, and other customers are looking at taking a step back. In a statement, a Scale AI spokesperson said its business, which spans work with major companies and governments, remains strong, as it is committed to protecting customer data. The company declined to comment on specifics with Google. Alexandr Wang, Scale's 28-year-old CEO who is coming to Meta as part of the deal, will remain on Scale's board but will have appropriate restrictions placed around his access to information, two sources familiar with the move confirmed. Large tech companies likely perceive the regulatory environment for AI partnerships as easier to navigate under President Donald Trump than under former President Joe Biden, said William Kovacic, director of the competition law center at George Washington University. Trump's antitrust enforcers have said they do not want to regulate how AI develops, but have also displayed a suspicion of large tech platforms, he added. "That would lead me to think they will keep looking carefully at what the firms do. It does not necessarily dictate that they will intervene in a way that would discourage the relationships," Kovacic said. Federal Trade Commission probes into past "aquihire" deals appear to be at a standstill. Under the Biden administration, the FTC opened inquiries into Amazon's deal to hire top executives and researchers from AI startup Adept, and Microsoft's $650 million deal with Inflection AI. The latter allowed Microsoft to use Inflection's models and hire most of the startup's staff, including its co-founders. Amazon's deal closed without further action from the regulator, a source familiar with the matter confirmed. And, more than a year after its initial inquiry, the FTC has so far taken no enforcement action against Microsoft over Inflection, though a larger probe over practices at the software giant is ongoing. A spokesperson for the FTC declined to comment on Friday. David Olson, a professor who teaches antitrust law at Boston College Law School, said it was smart of Meta to take a minority nonvoting stake. "I think that does give them a lot of protection if someone comes after them," he said, adding that it was still possible that the FTC would want to review the agreement. The Meta deal has its skeptics. U.S. Senator Elizabeth Warren, a Democrat from Massachusetts who is probing AI partnerships involving Microsoft and Google, said Meta's investment should be scrutinized. "Meta can call this deal whatever it wants - but if it violates federal law because it unlawfully squashes competition or makes it easier for Meta to illegally dominate, antitrust enforcers should investigate and block it," she said in a statement on Friday. While Meta faces its own monopoly lawsuit by the FTC, it remains to be seen whether the agency will have any questions about its Scale investment. The U.S. Department of Justice's antitrust division, led by former JD Vance adviser Gail Slater, recently started looking into whether Google's partnership with chatbot creator was designed to evade antitrust review, Bloomberg News reported. The DOJ is separately seeking to make Google give it advance notice of new AI investments as part of a proposal to curb the company's dominance in online search.
Time of India
41 minutes ago
- Time of India
US pharma bets big on China to snap up potential blockbuster drugs
U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads ( Originally published on Jun 16, 2025 ) U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters."They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData.A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%."I think it's only accelerating," Gleason Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs."The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio . That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals.'WAKEUP CALL'By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say.U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week."We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time."Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry."It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
Hindustan Times
an hour ago
- Hindustan Times
Trump Mobile's T1 phone: How much will the gold smartphone cost and how to pre-order now?
The Trump family on Monday said it is starting a new mobile phone service. The president's son, Eric, said that the new venture is called Trump Mobile and it will sell phones that will be built in the US. He further announced a new mobile phone and service, called T1 Phone, which will be gold and is 'proudly designed and built in the United States'. The T1 Phone is currently available for pre-order, per the Trump Mobile website. The phone will be available in September. Customers can also subscribe to 'Trump Mobile' with their current mobile device. Read More: Trump Mobile released, T1 phone to be launched Sept 2025 | What do they offer? 'Hard-working Americans deserve a wireless service that's affordable, reflects their values, and delivers reliable quality they can count on,' Eric Trump said in a statement on Monday. The Trump Organization said the new, gold-coloured phone available for USD 499 in August, called the T1 Phone, won't be designed or made by Trump Mobile, but by another company. Retail Price: The T1 Phone is priced at $499. A $100 deposit is required for pre-orders. Service Plan: The accompanying '47 Plan' costs $47.45/month, offering unlimited talk, text, and data, plus extras like telehealth and roadside assistance. Announced Release: Trump Mobile's press release states the T1 Phone will launch in August 2025, but the official website lists September 2025. Pre-Order Status: Pre-orders are open as of June 16, 2025, with a $100 deposit. Read More: Trump Mobile copying Obama's phone strategy? Here's how the two plans are different The T1 runs Android 15 with a 6.8-inch AMOLED display (120Hz), 50MP main camera, 12GB RAM, 256GB expandable storage, 5,000mAh battery, and features like a headphone jack and AI Face Unlock. However, the chipset is unspecified, and the camera quality is questioned. A 250-seat customer service center will be set up in the US to assist subscribers. Customers will be able to switch to the Trump Mobile network with their current phones,or connect with the new Android-based T1.
